Increasing transparency has become a high priority for regulatory
agencies around the globe, and this week, the US Food and Drug
Administration (FDA) released a transparency plan outline that includes
eight proposals for further consideration. The broad proposals focus on
improving the quality of, and access to, FDA’s compliance and
enforcement data. In a separate development, two clinical researchers
are leading the call for all clinical data from drug trials and device
studies to be disclosed, regardless of whether the research was a
success or not. They argue such disclosure would improve research and
allow more efficient use of resources. The FDA plan does not directly
address clinical data.
Read more: